We interrogated a large clinical cohort of patients with breast cancers which received tumor sequencing using the FDA-cleared, tumor-normal, MSK-IMPACT assay (40, 90, 91), which provides sequencing coverage spanning the CDK4 and CDK6 exonic regions. Here, CDK6 is linked to neoplasm.